The UK and US have announced a important commercial pact that will guarantee no tariffs on UK drug shipments being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the NHS. This commitment ensures that import taxes on these key products will stay at nothing for a timeframe of three years.
This agreement follows recent threats to significantly raise import taxes on branded drug products, with increases mentioned up to 100%.
"This agreement between the United Kingdom bolsters the international landscape for innovative medicines and introduces long-overdue balance to American-British medicine commerce," a release noted.
Economic Impact
Pharmaceuticals constitute one of the Britain's largest goods shipped to the United States, which is by far the biggest destination for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This guarantee safeguards employment, increases capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Key NHS Changes
The deal includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to increase total public funding on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at 15%. In the past, rebates topped 20%.
Broader Context
The deal takes place against a protracted tension between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by assertions that American customers were charged a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while major investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its total funding over the last ten years.
